Atherosclerosis Research
Atherosclerosis is a disease of the arterial system that is characterized by the accumulation of fatty deposits within arterial walls, known as 'atherosclerotic plaques'.
Atherosclerosis Research Products Targets
- PI 3-kinase (22)
- HMG-CoA Reductase (8)
- Matrix Metalloprotease (16)
- LXR-like Receptor (6)
- Elastase (1)
- Cell Adhesion Molecule (21)
- Lipoxygenase (8)
- Leukotriene and Related Receptor (13)
- Others (7)
- Cytokine Receptor (4)
- Cyclooxygenase (24)
- IRAK (1)
- PPARγ (16)
- PPARδ (5)
- PPARα (7)
- Angiotensin-Converting Enzyme (8)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Urotensin-II Receptor (8)
- Angiotensin AT2 Receptor (3)
- Angiotensin AT1 Receptor (9)
- SREBP (2)
- GPBA Receptor (3)
- Phospholipase (16)
- Prostanoid Receptor (24)
- Cytokine (15)
- Platelet-Activating Factor (PAF) Receptor (5)
Products for Atherosclerosis Research - Page 20
- Cat.No. Product Name Information/Activity
-
BCC6184
Fatostatin A
298197-04-3
-
BCC6009
PF 429242
947303-87-9
-
BCC7381
(±)-AC 7954 hydrochloride
477313-09-0
-
BCC5796
Urotensin II (human)
Urotensin II (114-124), human, an 11-amino acid residue peptide, is a potent vasoconstrictor and agonist for the orphan receptor GPR14.
-
BCC8010
GSK 1562590 hydrochloride
1003878-07-6
-
BCC6257
SB 611812
345892-71-9
-
BCC7713
SB 657510
SB-657510 is a selective urotensin II (UII) receptor (UT) antagonist. The Ki values are 61, 17, 30, 65 and 56 nM for human, monkey, cat, rat and mouse receptors, respectively. SB-657510 exerts anti-inflammatory effects by inhibiting UII-induced upregulation of inflammatory mediators such as adhesion molecules, cytokines, and tissue factor in human vascular endothelial cells.
-
BCC6256
SB 706375
733734-61-7
-
BCC5917
UFP 803
879497-82-2
-
BCC5985
[Orn5]-URP
782485-03-4
![[Orn5]-URP chemical structure](/media/images/struct/BCC5985.png)
